Why Is TFF Pharmaceuticals (TFFP) Stock Tanking Today - (TFFP)

TFF Pharmaceuticals Inc TFFP shares are tumbling after program updates for Voriconazole Inhaled Powder (TFF VORI) and Tacrolimus Inhaled Powder (TFF TAC) clinical programs.
The company expects to deliver preliminary patient data from the Phase 2 study of TFF VORI in the first quarter of 2023 and TFF TAC in the second quarter of 2023.
The timing of data release has been updated due to several challenges related to staffing shortages, shipping, and global supply chain delays.
"Clinical trial operations and logistics for much of the pharmaceutical industry, including TFF, continue to be impacted by ongoing staffing shortages and global supply chain constraints, which have subsequently led to challenges in predicting enrollment and data readouts," said Glenn Mattes, CEO
Concurrently, the company announced that a second patient had been treated with its proprietary Voriconazole Inhalation Powder (TFF VORI) through a compassionate use program.
TFF VORI is a next-generation, direct-to-lung, inhaled dry powder formulation of voriconazole for Invasive Pulmonary Aspergillosis.
The patient had a history of skin cancers and multiple fungal infections.
Following the initiation of TFF VORI therapy, the patient's lung function stabilized, and no dose modification of tacrolimus was required.
Price Action: TFFP shares are down 37.8% at $1.68 on the last check Wednesday.

Why TFF Pharmaceuticals Shares Are Sinking Today?